Morgan Stanley Maintains Underweight on Franklin Resources, Lowers Price Target to $28

Morgan Stanley analyst Mike Cyprys maintains Franklin Resources (NYSE:BEN) with a Underweight and lowers the price target from $30 to $28.

byBenzinga Newsdesk

April 8, 2022

1 minute read

Morgan Stanley analyst Mike Cyprys maintains Franklin Resources (NYSE:BEN) with a Underweight and lowers the price target from $30 to $28.

Credit Suisse Initiates Coverage On CSX with Outperform Rating, Announces Price Target of $35

By Benzinga Newsdesk

Today, 8:00 AM

Credit Suisse analyst Ariel Rosa initiates coverage on CSX (NASDAQ:CSX) with a Outperform rating and announces Price Target of $35.

CSX

News

‘HBO/HBO Max Layoffs Hit Max Reality, Acquisitions, Casting & Int’l; Amy Gravitt & Sarah Aubrey Get New Duties In Reorg’ -Deadline Report

By Benzinga Newsdesk

Today, 8:00 AM

https://deadline.com/2022/08/hbo-max-layoffs-reality-amy-gravitt-sarah-aubrey-reorg-acquisitions-casting-international-1235091596/

WBD

CrossAmerica Partners Q2 EPS $0.35 Beats $0.33 Estimate, Sales $1.48B Up From $859.33M YoY

By Benzinga Newsdesk

Today, 8:00 AM

CrossAmerica Partners (NYSE:CAPL) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.33 by 6.06 percent. This is a 169.23 percent increase over earnings of $0.13 per share from

CAPL

Neurocrine Biosciences Q4 Adjusted EPS $1.24 Beats $1.14 Estimate, Sales $412.00M Beat $409.09M Estimate

By Benzinga Newsdesk

Today, 8:00 AM

Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.24 per share which beat the analyst consensus estimate of $1.14 by 8.77 percent. This is a 3000 percent increase over earnings of $0.04 per share

NBIX

Morgan Stanley Maintains Underweight on Franklin Resources, Lowers Price Target to $28

Related Posts

Credit Suisse Initiates Coverage On CSX with Outperform Rating, Announces Price Target of $35

‘HBO/HBO Max Layoffs Hit Max Reality, Acquisitions, Casting & Int’l; Amy Gravitt & Sarah Aubrey Get New Duties In Reorg’ -Deadline Report

CrossAmerica Partners Q2 EPS $0.35 Beats $0.33 Estimate, Sales $1.48B Up From $859.33M YoY

Neurocrine Biosciences Q4 Adjusted EPS $1.24 Beats $1.14 Estimate, Sales $412.00M Beat $409.09M Estimate